In other countries
The same active substances on other registers, the same brand first.
- OpdualagBrazil · Bristol-Myers Squibb Farmacêutica LtdaSame brand
- OpdualagCanada · 240 MG / 20 ML + 80 MG / 20 ML · Solution · Bristol-Myers Squibb CanadaSame brand
- Opdualag 240 MG/80 MG Concentrado Para Solucion Para PerfusionSpain · 85,20 mg + 255,60 mg · concentrado para solución para perfusión · Bristol-Myers Squibb Pharma EeigSame brand
- OpdualagEuropean Union · Bristol-Myers Squibb Pharma EEIGSame brand
- OpdualagItaly · Concentrato per soluzione per infusione · Bristol-Myers Squibb Pharma EeigSame brand
- Opdualag 80 mg/240 mg, concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · Bristol-Myers Squibb Pharma EEIGSame brand
- Opdualag Concentrate for Solution for Infusion 240MG/80MGSingapore · 240mg per vial + 80mg per vial · infusion, solution concentrate · Bristol-Myers Squibb (Singapore) Pte. LTD.Same brand
- OpdualagUnited States · 240MG; 80MG · solution · Bristol Myers SquibbSame brand
Sources and licences
Compiled by Prognia from the public register below; the register’s text is the official one.
HALMED — Agencija za lijekove i medicinske proizvode RH
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH NN 67/2017 · Added 8 Oct 2026
Report an error or request removalCorrections from the holder or the register are welcome.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Active substances
- Nivolumab, Relatlimab
- Register
- Croatia (HALMED)
- Status
- Authorised
- Registration
- 16718
- ATC code
- L01FY02
- Procedure
- EU centralised
- Supply
- na recept; u ljekarni